

Special Issue

New Insights of Management of Hepatocellular Carcinoma

Message from the Guest Editors

After a long dry spell, HCC treatment paradigms have rapidly changed in recent years. Introduction of immunotherapy and immunotherapy-based treatment concepts in clinical routine became a door opener for new treatment concepts in this hard-to-treat disease. Immunotherapeutic-based combinations regimens in particular show highly objective responses rates, offering the use of these concepts in advanced disease for downstaging or rendering metastatic disease to potentially curative treatment. This Special Issue of *Cancers* invites manuscripts focusing on treatment concepts and biomarkers which might help to identify special patient populations, treatment concepts, or biomarkers who show high responses and might guide the choice of treatment. Prof. Dr. Oliver Waidmann

Guest Editors

Prof. Dr. Oliver Waidmann

Dr. Fabian Finkelmeier

Dr. Vera Himmelsbach

Deadline for manuscript submissions

closed (31 August 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/110042

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)